about
Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's DiseaseAcquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: a case report.A case of TAFRO syndrome, a variant of multicentric Castleman's disease, successfully treated with corticosteroid and cyclosporine A.International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.Multicentric Castleman's disease with voltage-gated potassium channel antibody-positive limbic encephalitis: a case report.Unicentric Castleman's disease: an uncommon cause of posterior mediastinal massRetroperitoneal Castleman's disease: advocating a multidisciplinary approach for a rare clinical entity.Unicentric mixed variant Castleman disease associated with intrabronchial plasmacytoma.Intra-abdominal localized hyaline-vascular Castleman disease: imaging characteristics and management of a rare condition.[Multicentric Castleman disease not associated with HHV-8 and HIV viruses].Multicentric Castleman's Disease and Kaposi's Sarcoma in a HIV-Positive Patient on Highly Active Antiretroviral Therapy.Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease.Systemic lymphadenopathy with systemic sclerosis and Sjögren's syndrome: a case report.The full spectrum of Castleman disease: 273 patients studied over 20 years.Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?TAFRO syndrome: An atypical variant of KSHV-negative multicentric Castleman disease.KSHV induces immunoglobulin rearrangements in mature B lymphocytes.A Case of Spondyloarthritis in Patient Affected by Unicentric Castleman's Disease Effectively Managed with Surgery Resection and Tocilizumab Treatment.Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease.Anemia and autoimmunity markers in an adolescent with Castleman disease.Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements.
P2860
Q26772331-EE107376-DA7D-4183-A88D-0C88BFF72562Q33415463-4340292C-4996-4805-A401-C6D3291E2D51Q33433871-00C743D7-BC03-4142-B338-E5ED2B82A593Q33438403-A488B9F5-83DA-4DA5-BCB0-2BF15BB0FA0FQ35554559-9AF6F477-B555-419E-B722-8A32CACFCA9BQ36986638-88CEFA2D-AAE4-4720-965A-734D28845040Q37685166-82928BBD-E8C2-45E4-98E5-91B794FFD412Q37715422-322C8ED4-AC63-422C-BB77-F1E207659DEEQ38464968-86ECABDE-3D61-4E3F-836D-14317C1BE05BQ41518572-9525D8BA-ED81-48EF-9874-836B48DC1DC3Q41718738-5C6DE471-408C-49A3-9287-452104568AE2Q44262025-47AAD73B-8DCB-4983-9CD5-E90BBDAD8EABQ46362154-418415B0-E863-4A34-96BF-09ABA529F19BQ47578601-426CB8E6-4891-45FF-9130-36FE236160D8Q48287167-7133303C-2322-4E93-999F-8C77312DAAC1Q50925943-BC60B265-99BF-47B5-B568-029F21DC46A6Q52586065-C1D8E17B-27C0-4BEC-AE62-FC4CA72CBFB7Q52611522-1C9F72DC-5AC3-48EE-9432-106BFCE182FDQ52614425-413DBE42-53AF-4F5D-B293-D0D0A1A15449Q52990816-50EC7E8C-E7D2-4899-9230-5A36AE383B05Q55024047-DCF8F14E-FAB1-4AEB-A6B7-EA363D4F7132
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Castleman disease and associated autoimmune disease.
@en
Castleman disease and associated autoimmune disease.
@nl
type
label
Castleman disease and associated autoimmune disease.
@en
Castleman disease and associated autoimmune disease.
@nl
prefLabel
Castleman disease and associated autoimmune disease.
@en
Castleman disease and associated autoimmune disease.
@nl
P2093
P1476
Castleman disease and associated autoimmune disease.
@en
P2093
Bruce A Peterson
Jerry A Molitor
Theresa W Muskardin
P356
10.1097/BOR.0B013E32834DB525
P577
2012-01-01T00:00:00Z